CUSIP: 13739U104
Q2 2016 13F Holders as of 30 Jun 2016
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
1,820,340
-
Share change
-
+539,550
-
Total reported value
-
$3,620,000
-
Price per share
-
$1.99
-
Number of holders
-
28
-
Value change
-
+$993,683
-
Number of buys
-
14
-
Number of sells
-
12
Quarterly Holders Quick Answers
What is CUSIP 13739U104?
CUSIP 13739U104 identifies CGIX - CANCER GENETICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q3 2016
-
Previous quarter:
Q1 2016
Recent filing periods for CUSIP 13739U104:
Institutional Holders of CANCER GENETICS INC - COM (CGIX) as of Q2 2016
As of 30 Jun 2016,
CANCER GENETICS INC - COM (CGIX) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
1,820,340 shares.
The largest 10 holders included
PERKINS CAPITAL MANAGEMENT INC, VANGUARD GROUP INC, Fairbanks Capital Management, Inc., SABBY MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, EAGLE GLOBAL ADVISORS LLC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Fund Advisors, DIKER MANAGEMENT LLC, and TOCQUEVILLE ASSET MANAGEMENT L.P..
This page lists
28
institutional shareholders reporting positions in this security
for the Q2 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.